Merck reports Phase I/II data for Btk inhibitor M7583 in B cell malignancies

Merck KGaA (Xetra:MRK) reported data from 3 evaluable patients with relapsed or refractory B cell malignancies in the dose-escalation Part 1 of a Phase I/II trial showing that once-daily 80 mg M7583 for days 1-3 followed by once-daily 160 mg M7583 for the remainder of each 28-day cycle led to an objective response or stable disease in all 3 patients after 4 cycles of treatment. Data were presented at the American Society of Clinical Oncology meeting in Chicago.

The open-label, European trial consists of the dose-escalation Part 1 in patients with relapsed or refractory B cell malignancies followed by the dose-expansion Part 2 in patients with diffuse large B cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) who have failed 1-3 prior lines of therapy...